CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer

被引：0
|
作者：
Forstmeyer, D. [1 ]
机构：
[1] Univ Klinikum Leipzig, Univ Krebszentrum Leipzig UCCL, Liebigstr 20, D-04103 Leipzig, Germany
来源：
ONKOLOGE | 2016年 / 22卷 / 07期
关键词：
PALBOCICLIB;
D O I：
10.1007/s00761-016-0055-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：507 / 508
页数：2
相关论文
共 50 条
  • [41] Treatment differences by race and age in metastatic hormone receptor-positive/HER2-negative breast cancer
    Abdou, Yara
    Ivory, Joannie
    Deal, Allison
    Wardell, Ally
    Wheless, Amy
    Dees, Claire
    Carey, Lisa
    CANCER RESEARCH, 2024, 84 (09)
  • [42] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Minetta C. Liu
    Javier Cortés
    Joyce O’Shaughnessy
    Cancer and Metastasis Reviews, 2016, 35 : 323 - 332
  • [43] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Liu, Minetta C.
    Cortes, Javier
    O'Shaughnessy, Joyce
    CANCER AND METASTASIS REVIEWS, 2016, 35 (02) : 323 - 332
  • [44] Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
    Glaviano, Antonino
    Wander, Seth A.
    Baird, Richard D.
    Yap, Kenneth C. -H.
    Lam, Hiu Yan
    Toi, Masakazu
    Carbone, Daniela
    Geoerger, Birgit
    Serra, Violeta
    Jones, Robert H.
    Ngeow, Joanne
    Toska, Eneda
    Stebbing, Justin
    Crasta, Karen
    Finn, Richard S.
    Diana, Patrizia
    Vuina, Karla
    de Bruin, Robertus A. M.
    Surana, Uttam
    Bardia, Aditya
    Kumar, Alan Prem
    DRUG RESISTANCE UPDATES, 2024, 76
  • [45] Real World Statistics on CDK4/6 Inhibitor Use in Metastatic Hormone Receptor Positive and HER2-Negative Breast Cancer with a Focus on Age
    Monahan, Kathleen
    Kamaraju, Sailaja
    Cheng, Yee Chung
    Retseck, Janet
    Sriram, Deepika
    Burfeind, John
    Chitambar, Christopher
    Chaudhary, Lubna N.
    CANCER RESEARCH, 2023, 83 (05)
  • [46] CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: A network meta-analysis (NMA) of randomized controlled trials (RCTs).
    Husnain, Muhammad
    Bin Riaz, Irbaz
    Gondal, Farva R.
    Malik, Saad
    Sipra, Qurat U. I. Ain Riaz
    Raina, Ammad
    Islam, Mahnoor
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Peripheral blood lymphocyte counts predict clinical outcomes in patients with hormone receptor-positive HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
    Vernieri, C.
    Zattarin, E.
    Mariani, L.
    Menichetti, A.
    Leporati, R.
    Ligorio, F.
    Fuca, G.
    Lobefaro, R.
    Griguolo, G.
    Sirico, M.
    Bernocchi, O.
    Marra, A.
    Agostinetto, E.
    Jacobs, F.
    Di Mauro, P.
    Curigliano, G.
    Pedersini, R.
    Losurdo, A.
    Generali, D.
    Dieci, M. V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S641 - S642
  • [48] CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches
    Parola, S.
    Di Lauro, V.
    De Placido, P.
    Forestieri, V.
    Buono, G.
    von Arx, C.
    Pietroluongo, E.
    Pagliuca, M.
    Cianniello, D.
    Lauria, R.
    Caputo, R.
    Arpino, G.
    de Placido, S.
    Giuliano, M.
    De Laurentiis, M.
    De Angelis, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S172 - S173
  • [49] Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
    Manabu Futamura
    Takahiro Nakayama
    Tetsuhiro Yoshinami
    Chiya Oshiro
    Mikiya Ishihara
    Midori Morita
    Akira Watanabe
    Azusa Tanigichi
    Masami Tsukabe
    Masafumi Shimoda
    Kanae Nitta
    Yoko Chihara
    Hiroyuki Yasojima
    Yoshimi Ouchi
    Yoshihisa Tokumaru
    Norikazu Masuda
    Breast Cancer, 2023, 30 : 943 - 951
  • [50] Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
    Futamura, Manabu
    Nakayama, Takahiro
    Yoshinami, Tetsuhiro
    Oshiro, Chiya
    Ishihara, Mikiya
    Morita, Midori
    Watanabe, Akira
    Tanigichi, Azusa
    Tsukabe, Masami
    Shimoda, Masafumi
    Nitta, Kanae
    Chihara, Yoko
    Yasojima, Hiroyuki
    Ouchi, Yoshimi
    Tokumaru, Yoshihisa
    Masuda, Norikazu
    BREAST CANCER, 2023, 30 (06) : 943 - 951
12345